Snodgres Jon
Known title: Chief Financial OfficerCIK: 0001613498
Associated companies
Transaction History
| RGEN | ▼ Sell | Tax Withholding | 710 | $109K | 5/16/2023 | View on chart |
| RGEN | ▲ Buy | Grant | 8,795 | $0 | 3/3/2023 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 3,674 | $691K | 3/3/2023 | View on chart |
| RGEN | ▲ Buy | Grant | 4,848 | $0 | 3/2/2023 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 521 | $90K | 2/28/2023 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 682 | $118K | 2/28/2023 | View on chart |
| RGEN | ▼ Sell | Open Market | 5,647 | $1.1M | 2/16/2023 | View on chart |
| RGEN | ▲ Buy | Option Exercise | 466 | $28K | 10/7/2022 | View on chart |
| RGEN | ▲ Buy | Option Exercise | 3,047 | $262K | 8/16/2022 | View on chart |
| RGEN | ▲ Buy | Option Exercise | 970 | $209K | 8/16/2022 | View on chart |
| RGEN | ▼ Sell | Open Market | 4,298 | $1.1M | 8/16/2022 | View on chart |
| RGEN | ▼ Sell | Open Market | 2,400 | $608K | 8/16/2022 | View on chart |
| RGEN | ▼ Sell | Open Market | 2,000 | $440K | 8/1/2022 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 712 | $107K | 5/13/2022 | View on chart |
| RGEN | ▲ Buy | Option Exercise | 2,952 | $100K | 3/8/2022 | View on chart |
| RGEN | ▲ Buy | Option Exercise | 1,214 | $72K | 3/8/2022 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 661 | $130K | 2/28/2022 | View on chart |
| RGEN | ▲ Buy | Grant | 5,922 | $0 | 2/28/2022 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 2,468 | $485K | 2/28/2022 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 695 | $137K | 2/27/2022 | View on chart |
| RGEN | ▲ Buy | Grant | 3,443 | $0 | 2/24/2022 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 269 | $51K | 2/24/2022 | View on chart |
| RGEN | ▲ Buy | Grant | 900 | $0 | 2/17/2022 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 332 | $61K | 2/17/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Repligen Completes BioLife Solutions Acquisition
Repligen has finalized its acquisition of BioLife Solutions, a move that follows shareholder approval of the merger. This transaction expands Repligen's portfolio in the biopharmaceutical sector. The stock recently reached a 52-week high, reflecting market interest in the company's growth strategy.
Repligen Completes BioLife Solutions Acquisition. Repligen has finalized its acquisition of BioLife Solutions, a move that follows shareholder approval of the merger. This transaction expands Repligen's portfolio in the biopharmaceutical sector. The stock recently reached a 52-week high, reflecting market interest in the company's growth strategy.